Research Papers:

Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer

Mingxin Wen, Yongwon Kwon, Yongsheng Wang, Jian-Hua Mao and Guangwei Wei _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:25226-25239. https://doi.org/10.18632/oncotarget.4712

Metrics: PDF 2284 views  |   HTML 2396 views  |   ?  


Mingxin Wen1, Yongwon Kwon2, Yongsheng Wang1, Jian-Hua Mao2, Guangwei Wei1

1Department of Human Anatomy and Key Laboratory of Experimental Teratology, Ministry of Education, Shandong University School of Medicine, Jinan, Shandong, 250012 P.R. China

2Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94127, USA

Correspondence to:

Guangwei Wei, e-mail: [email protected]

Jian-Hua Mao, e-mail: [email protected]

Keywords: UBE2T, prostate cancer, metastasis, vimentin

Received: May 07, 2015     Accepted: July 17, 2015     Published: July 30, 2015


Increased expression of ubiquitin-conjugating enzyme E2T (UBE2T) is reported in human prostate cancer. However, whether UBE2T plays any functional role in prostate cancer development remains unknown. We here report the first functional characterization of UBE2T in prostate carcinogenesis. Prostate cancer tissue array analysis confirmed upregulation of UBE2T in prostate cancer, especially these with distant metastasis. Moreover, higher level of UBE2T expression is associated with poorer prognosis of prostate cancer patients. Ectopic expression of UBE2T significantly promotes prostate cancer cell proliferation, motility and invasion, while UBE2T depletion by shRNA significantly inhibits these abilities of prostate cancer cells. Xenograft mouse model studies showed that overexpression of UBE2T promotes whereas UBE2T depletion inhibits tumor formation and metastasis significantly. Collectively, we identify critical roles of UBE2T in prostate cancer development and progression. These findings may serve as a framework for future investigations designed to more comprehensive determination of UBE2T as a potential therapeutic target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4712